количество зарегистрированных пользователей: 69001

Rumedo Медицинский образовательный портал

МЕДИЦИНСКИЙ ОБРАЗОВАТЕЛЬНЫЙ ПОРТАЛ

Академия инновационного образования

БИБЛИОТЕКА

По категориям

По специальностям

  • Зарубежные материалы

    Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

    Дата публикации 22.10.2020
    Автор: Benjamin M. Scirica, M.D., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mosenzon, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D., for the SAVOR-TIMI 53 Steering Committee and Investigators

    The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

    Подробнее

    877

  • Зарубежные материалы

    High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes

    Дата публикации 22.10.2020
    Автор: L. J. M. Boonman-de Winter & F. H. Rutten & M. J. M. Cramer & M. J. Landman & A. H. Liem & G. E. H. M. Rutten & A. W. Hoes

    Aims/hypothesis The aim of this study was to assess the prevalence of (unknown) heart failure and left ventricular dysfunction in older patients with type 2 diabetes.

    Подробнее

    934

  • Зарубежные материалы

    Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007–2017

    Дата публикации 22.10.2020
    Автор: Thomas R. Einarson, Annabel Acs, Craig Ludwig and Ulrik H. Panton

    Te International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM). People with diabetes comprise 8.8% of the world’s population, and IDF predicts that the number of cases of diabetes will rise to 642 million by 2040

    Подробнее

    894

  • Зарубежные материалы

    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn, M.G. Silverman, T.A. Zelniker, J.F. Kuder, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, C.T. Ruff, I.A.M. Gause‑Nilsson, M. Fredriksson, P.A. Johansson, A.-M. Langkilde, and M.S. Sabatine, for the DECLARE–TIMI 58 Investigators

    The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium – glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.

    Подробнее

    714

  • Статьи

    Алгоритмы специализированной медицинской помощи больным сахарным диабетом (8-й выпуск)

    Дата публикации 22.10.2020
    Под редакцией: И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова

    Данное издание содержит девятый актуализированный выпуск (дополненный) клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.

    Подробнее

    943

  • Зарубежные материалы

    Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl. Biomath., Theresa Devins, Dr.P.H., Odd Erik Johansen, M.D., Ph.D., Hans J. Woerle, M.D., Uli C. Broedl, M.D., and Silvio E. Inzucchi, M.D., for the EMPA-REG OUTCOME Investigators

    The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

    Подробнее

    874

  • Зарубежные материалы

    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Rury R. Holman, F.Med.Sci., M. Angelyn Bethel, M.D., Robert J. Mentz, M.D., Vivian P. Thompson, M.P.H., Yuliya Lokhnygina, Ph.D., John B. Buse, M.D., Ph.D., Juliana C. Chan, M.D., Jasmine Choi, M.S., Stephanie M. Gustavson, Ph.D., Nayyar Iqbal, M.D., Aldo P. Maggioni, M.D., Steven P. Marso, M.D., Peter Öhman, M.D., Ph.D., Neha J. Pagidipati, M.D., M.P.H., Neil Poulter, F.Med.Sci., Ambady Ramachandran, M.D., Bernard Zinman, M.D., and Adrian F. Hernandez, M.D., M.H.S., for the EXSCEL Study Group*

    The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.

    Подробнее

    671

  • Зарубежные материалы

    9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesd2019

    Дата публикации 22.10.2020
    Автор: American Diabetes Association

    The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care.

    Подробнее

    1149

  • Зарубежные материалы

    Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

    Дата публикации 22.10.2020
    Автор: E.A. Bohula, S.D. Wiviott, D.K. McGuire, S.E. Inzucchi, J. Kuder, K.A. Im, C.L. Fanola, A. Qamar, C. Brown, A. Budaj, A. Garcia‑Castillo, M. Gupta, L.A. Leiter, N.J. Weissman, H.D. White, T. Patel, B. Francis, W. Miao, C. Perdomo, S. Dhadda, M.P. Bonaca, C.T. Ruff, A.C. Keech, S.R. Smith, M.S. Sabatine, and B.M. Scirica, for the CAMELLIA–TIMI 61 Steering Committee and Investigators

    Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.

    Подробнее

    747

  • Зарубежные материалы

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Steven P. Marso, M.D., Stephen C. Bain, M.D., Agostino Consoli, M.D., Freddy G. Eliaschewitz, M.D., Esteban Jódar, M.D., Lawrence A. Leiter, M.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Julio Rosenstock, M.D., Jochen Seufert, M.D., Ph.D., Mark L. Warren, M.D., Vincent Woo, M.D., Oluf Hansen, M.Sc., Anders G. Holst, M.D., Ph.D., Jonas Pettersson, M.D., Ph.D., and Tina Vilsbøll, M.D., D.M.Sc., for the SUSTAIN-6 Investigators

    Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown.

    Подробнее

    791

  • Зарубежные материалы

    2018 ESC/ESH Guidelines for the management of arterial hypertension

    Дата публикации 22.10.2020
    Автор: Bryan Williams* (ESC Chairperson) (UK), Giuseppe Mancia* (ESH Chairperson) (Italy), Wilko Spiering (The Netherlands), Enrico Agabiti Rosei (Italy), Michel Azizi (France), Michel Burnier (Switzerland), Denis L. Clement (Belgium), Antonio Coca (Spain), Giovanni de Simone (Italy), Anna Dominiczak (UK), Thomas Kahan (Sweden), Felix Mahfoud (Germany), Josep Redon (Spain), Luis Ruilope (Spain), Alberto Zanchetti† (Italy), Mary Kerins (Ireland), Sverre E. Kjeldsen (Norway), Reinhold Kreutz (Germany), Stephane Laurent (France), Gregory Y. H. Lip (UK), Richard McManus (UK), Krzysztof Narkiewicz (Poland), Frank Ruschitzka (Switzerland), Roland E. Schmieder (Germany), Evgeny Shlyakhto (Russia), Costas Tsioufis (Greece), Victor Aboyans (France), and Ileana Desormais (France)

    The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)

    Подробнее

    831

  • Зарубежные материалы

    Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

    Дата публикации 22.10.2020
    Автор: Eri T. Kato, MD, MPH, PhD et al

    In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...

    Подробнее

    836

  • Зарубежные материалы

    Obesity and Diabetic Kidney Disease

    Дата публикации 22.10.2020
    Автор: Christine Maric-Bilkan, PhD. Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA

    The prevalence of obesity (body mass index, BMI ≥ 30 kg/m2) has risen to epidemic proportions and continues to be a major health problem worldwide 1–3. The high prevalence of obesity is closely linked to the increased incidence of a number of chronic diseases, including type 2 diabetes, hypertension and cardiovascular disease 2, 4–8.

    Подробнее

    1094

  • Зарубежные материалы

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (HHS Public Access)

    Дата публикации 22.10.2020
    Автор: Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D. for the LEADER Steering Committee on behalf of the LEADER Trial Investigators

    The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

    Подробнее

    982

  • Зарубежные материалы

    Diabetes with early kidney involvement may shorten life expectancy by 16 years

    Дата публикации 22.10.2020
    Автор: Chi Pang Wen, Chia Hsuin Chang, Min Kuang Tsai, June Han Lee, Po Jung Lu, Shan Pou Tsai, Christopher Wen, Chien Hua Chen, Chih Wen Kao, Chwen Keng Tsao and Xifeng Wu

    This study aimed to identify the excess risks associated with diabetic patients with early kidney involvement (early diabetic kidney disease). The mortality risks of early diabetic kidney disease, defined as diabetes in early stages 1-3 chronic kidney disease (CKD), were assessed from a cohort of 512,700 adults in Taiwan participating in a health surveillance program from 1994-2008. Three related ...

    Подробнее

    1207